A new antihypertensive strategy for black patients: Low-dose multimechanism therapy

Journal of the National Medical Association

Volumn 88, Issue 3, 1996, Pages 171-175

  Saunders, Elijah ^a   Neutel, Joel ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b NONE

Author keywords

Bisoprolol fumarate; Blacks; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BISOPROLOL; HYDROCHLOROTHIAZIDE;

AFRICAN AMERICAN; ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AFRICAN AMERICANS; ANTIHYPERTENSIVE AGENTS; BISOPROLOL; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; TREATMENT OUTCOME;

EID: 0030092760     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153: 154-183.
2. Saunders E. Drug treatment considerations for the hypertensive black patient. Clinical review. J Fam Pract. 1988;26: 659-664.
3. Croog SH, Kong BW, Levine S, et al. Hypertensive black men and women: quality of life and effects of antihypertensive medications. Arch Intern Med. 1990;150:1733-1741.
4. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
5. Ferdinand KC. New Joint National Committee recommendations as they affect black hypertensive patients. J Natl Med Assoc. 1989:81(suppl):31-40.
6. Cook CA. Pathophysiologic and pharmacotherapy considerations in the management of the black hypertensive patient. Am Heart J. 1988;116:288-295.
7. Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. Am J Cardiol. 1988;61:46H-52H.
8. Kaplan NM. The case for low dose diuretic therapy. Am J Hypertens. 1991;4:970-971.
9. Hall WD, Kong W. Hypertension in blacks: nonpharmacologic and pharmacologic therapy. In: Saunders E, ed. Cardiovascular Diseases in Blacks. Philadelphia, Pa: FA Davis Co; 1991.
10. DeQuattro V, Weir MR. Bisoprolol fumarate/-hydrochlorothiazide 6.25 mg: a new low-dose option for first-line antihypertensive therapy. Adv Ther. 1993;10:197-206.
11. Lewin AJ, Lueg MC, Targum S, Cardenas P. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in patients with mild to moderate hypertension. Clin Cardiol. 1993;16:732-736.
12. Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line, antihypertensive treatment. Clin Ther. 1993;15:779-787.
13. Giesecke HG, Buchner-Möll D. Three years of experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol. 1990;16(suppl 5):S175-S178.
14. Fogari R, Zoppi A, Pasotti C, et al. Effects of different beta-blockers on lipid metabolism in chronic therapy of hypertension. Int J Clin Pharmacol Ther Toxicol. 1988;26:597-604.
15. Neutel JM, Smith DHG, Ram CVS, et al. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Am J Cardiol. 1993;72:41-46.